Abstract: Decoding methods are provided for identifying populations in assays, particularly multiplexing assays and those associated with fluidic devices.

Abstract: Recombinant adeno-associated viral (AAV) capsid proteins are provided. Methods for generating the recombinant adeno-associated viral capsid proteins and a library from which the capsids are selected are also provided.

Abstract: A method for carrying out nucleic acid amplification, includes providing a reaction chamber, accommodating an array of nucleic acid probes at respective locations, for hybridizing to respective target nucleic acids; and introducing a solution into the reaction chamber, wherein the solution contains primers, capable of binding to target nucleic acids, nucleotides, nucleic acid extending enzymes and a sample including nucleic acids. The a structure of the nucleic acid probes and of the primers so that a hybridization temperature of the probes is higher than an annealing temperature of the primers, whereby hybridization and annealing take place in respective separate temperature ranges.

Abstract: The invention relates to the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. In another aspect, the invention relates to compounds of formula (II): processes for making these compounds, and the use thereof in the chemical synthesis of oligonucleotides, e.g., oligoribonucleotides. The invention also relates to methods of synthesis of oligomers, including but not limited to oligopeptides, oligosaccharides and oligonucleotides, particularly oligoribonucleotides and also oligodeoxyribonucleotides, in solution systems, and ionic tag linkers for use in methods provided herein.

Abstract: The present disclosure provides methods for screening subjects at a subordinate location within a geographic region, or a subordinate space within the subordinate location for an infectious agent. Such methods may comprise assigning a risk score to each of the one or more subordinate locations or subordinate spaces based on an amount of infectious agent in pooled environmental samples and pooled biological samples in a subordinate location or subordinate space as compared to each other subordinate location or subordinate space, and then screening biological samples from subordinate locations or subordinate spaces that have a higher risk score before screening biological samples from subordinate locations or subordinate spaces that have a lower risk score. Methods for determining a risk of a viral infection in one or more geographic regions are also provided.

Abstract: Provided is a method for detecting pathogenic microorganisms in a biological sample, which is a technique that can be used to perform high-sensitivity detection of pathogenic microorganisms, such as influenza virus, etc.

Abstract: Methods and systems are provided for point-of-care nucleic acid amplification and detection. One embodiment of the point-of-care molecular diagnostic system includes a cartridge and an instrument. The cartridge can accept a biological sample, such as a urine or blood sample. The cartridge, which can comprise one or more of a loading module, lysis module, purification module and amplification module, is inserted into the instrument which acts upon the cartridge to facilitate various sample processing steps that occur in order to perform a molecular diagnostic test.

Abstract: A method of preparing a nucleic acid sample with target enrichment uses a reaction vessel, within which is added a chelating agent to a sample with heating to about 99° C. to provide a crude lysate. A PNA probe is provided at a concentration sufficient for binding and capture of discernible levels of target nucleic acid. The PNA probe may be attached to beads which are initially embedded in a wax body and are released during the heating so that the y are free to move and come into contact with the PNA probe and target DNA. After binding has occurred, the beads are magnetically attracted back into a pocket along with the wax, which is allowed to solidify before they are removed from the reaction vessel.

Abstract: The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treatment regime. The methods may also be used to evaluate protein and/or metabolite levels that correlate with such clinical conditions. The methods are also of use to ascertain the probability outcome for a patient's particular prognosis.

Abstract: A composition includes a polymer including extending chains, side chains, or branches. One (or more) of a plurality of a first strand of nucleic acid is attached to each of a plurality of the side chains. One (or more) of a plurality of a second strand of nucleic acid, which is complementary to the first strand of nucleic acid, is complexed to each of the plurality of the first strand of nucleic acid to form a double strand of nucleic acid on each of the plurality of the side chains. At least one fluorescent compound is associated with the double strand of nucleic acid on each of the plurality of the side chains.

Abstract: A method of preventing protein glycation using a supplement may comprise: administering a supplement comprising lysine and zinc; monitoring a concentration of glucose before and after the supplement is administered in a bio-sample; and determining a change in a dose of the supplement based on the concentration of glucose found in the bio-sample.

Abstract: The invention relates to a method that detects the target substance by measuring a decrease in the optical signal generated by applying a first magnetic field to move the conjugate in the direction parallel to or away from the surface, etc. The invention also relates to an optical detection device wherein a liquid holding part has a sensing plate that can form a near field on a surface with light irradiated from a side of a rear face under a condition of total reflection, the liquid holding part being capable of holding a liquid sample that has a target substance and a magnetic particle that forms a conjugate with the target substance on the surface of the sensing plate, a light irradiation unit, a light detection unit, and a magnetic field application unit configured to apply a magnetic field to move the conjugate in the direction parallel to or away from the surface, etc.

Abstract: The application relates to hepatic fibrosis, specifically to hepatic fibrosis that may appear in a patient infected with one or more hepatitis viruses and/or who is suffering from hepatitis, specifically chronic hepatitis. The application provides methods and means for determining the stage (or degree) of hepatic fibrosis of such a patient. Specifically, the methods and means of the application make it possible to determine whether or not the stage (or degree) of hepatic fibrosis of the patient has exceeded the stage of light fibrosis. The methods and means of the invention use a combination of biomarkers such as, in particular, the CXCL10 protein and hyaluronic acid (HA).

Abstract: Methods for identifying and treating cancer patients likely to respond to topoisomerase inhibitors or likely to fail to respond to topoisomerase inhibitors are provided. The methods take advantage of the newly discovered role of BAF complexes in decatenation of DNA by topoisomerase IIa. Cancer cells are frequently at least partly defective in BAF complex activity. Such cells are targeted for therapy using certain topoisomerase IIa inhibitors according to the disclosed methods of treatment. Therapy of such cells using other topoisomerase inhibitors should be avoided.

Abstract: The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in an individual. The polypeptides and vaccines comprise T cell and/or B cell epitopes that are immunogenic in a high percentage of individuals in the human population.

Abstract: Several embodiments disclosed herein relate generally to methods and compositions for the generation of biological pacemakers. In some embodiments, the methods comprise contacting non-pacemaker cells with one or more transcription factors (in vivo or in vitro) and inducing pacemaker functionality in the cells.

Abstract: Presented herein are methods and compositions for multiplexed single cell gene expression analysis. Some methods and compositions include the use of droplets and/or beads bearing unique barcodes such as unique molecular barcodes (UMI).

Abstract: The present invention stems from the finding that two genes designated R2R1 and R2R2, play important roles in tissue development and cancer biology. In particular, the inventors have discovered that these two genes are expressed in pulmonary cells and are required for late branching morphogenesis of pulmonary epithelium and endothelium and support the development/maintenance of the refined three dimensional architecture of the lung. These genes are essential in the squamous differentiation program and development/maintenance of the progenitor (Krt14 expressing) cell pool. Moreover, the inventors have identified crucial roles for these genes in cancer biology, particularly processes associated with the acquisition of an immortal and metastatic phenotype (including cancer progression and metastasis) and pulmonary and cardiac development. Accordingly, the invention provides compounds and methods for use in the treatment of cardiac and pulmonary diseases and well as in cancer.

Abstract: Disclosed herein are various methods, systems, and compositions for the growth independent detection of cells such as microorganisms including bacteria. While existing cellular detection methodologies benefit from cell growth, the methods, systems, and compositions disclosed herein demonstrate embodiments that are independent of cell growth while still allowing for cell-based detection.

Abstract: In embodiments there is described a method for reducing false positives and negatives in the detection of SARS-CoV-2 in suspected patients using mass spectroscopy employing the steps of mixing samples of collected saliva and nasopharyngeal secretions in a single sample container; adding universal transport medium to the mixed samples in said single sample container; transporting the single sample container at a temperature above 0° C. to a remote location; deactivation of viral content of the mixed sample; protein digestion of the mixed sample; concomitant separation of peptides, ionization by mass spectroscopy of the separated peptides, and comparison of peptide patterns to known SARS-CoV-2 peptides. Also set forth in an embodiment is a collection container for collecting saliva and/or sputum, as well as a swab member, with universal transport medium and/or virus inactivating agent housed in separate compartment communicable with sample compartment through a one-way valve.

Abstract: The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treatment regime. The methods may also be used to evaluate protein and/or metabolite levels that correlate with such clinical conditions. The methods are also of use to ascertain the probability outcome for a patient's particular prognosis.

Abstract: Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.

Abstract: Disclosed herein are recombinant polypeptides comprising an elastin-like peptide (ELP) and a scFv, or a biological equivalent of the scFv. Also disclosed are compositions containing scFv-ELP polypeptides and methods of use.

Abstract: Disclosed are recombinant insect ferritin nanoparticles that can be used to display two different trimeric antigens at an equal ratio. Also disclosed are nucleic acids encoding the recombinant insect ferritin nanoparticles and methods of producing the recombinant insect ferritin nanoparticles. Methods for eliciting an immune response in a subject are also provided.

Abstract: An air sampling device is disclosed which includes one or more air sampling cassettes, with each cassette having a cassette internal diameter and a sample collection media disposed within the cassette internal diameter. The sum of the interior diameters of the air sampling cassettes is from about 2.5 mm to about 65 mm. The device also includes a sampling device casing having one or more air inlet orifices, an air outlet orifice, and an interior passageway in flow communication with both air inlet orifices and the air outlet orifice. One air sampling cassette is attached to each air inlet orifice. The device also includes a fan for drawing air through the air sampling cassettes and the interior passageway at an air flow rate. The device produces a noise level of less than 40 dBA, measured at a distance of 1 foot from the air outlet orifice, when the air flow rate is from about 0.5 to about 2.0 liters per minute. A method for air sampling is also disclosed.

Abstract: Methods and compositions are provided for the analysis of rare cells or other biological entities in a population, by contacting the population with a labeling nanoparticle comprising a VLP conjugated to a light emitting moiety and a specific binding moiety, then detecting the presence of bound nanoparticle by light emission.

Abstract: The systems and methods contained herein are directed toward automated analysis of agglutination reactions to determine properties of materials, including viruses and vaccines thereto. Advanced digital imaging and processing techniques are used to determine the presence or absence of viruses or antibodies within a fluid sample. The systems and methods are versatile, and can be used to determine specific properties of biomaterials and viruses, such as titer value, concentration, genotype, phenotype, serotype, vaccine efficacy, viral resistance and other properties of relevance in the medical, research and development fields. Also provided are systems and methods of standardization, repeatability, and data storage and transmittal to reduce errors and subjectivity inherent to conventional assays characterized by human readers.

Abstract: The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS CoV-2 infection and SARS-CoV infection, using the SARS-CoV and SARS-CoV-2 nucleocapsid proteins and antibodies binding to these proteins. The invention encompasses reagents, methods and kits for the detection of a SARS-associated coronavirus.

Abstract: The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of a Sirtuin (SIRT), in particular, by targeting natural antisense polynucleotides of a Sirtuin (SIRT). The invention also relates to the identification of these antisense oligonucleotides and their use in treating diseases and disorders associated with the expression of Sirtuins (SIRT)s.

Abstract: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3?UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.

Abstract: Methods and techniques to increase the reliability of detecting virus infections, particularly lymphotropism, to eliminate false negative reactions in testing blood for the presence of lymphotropic viruses during enzyme immunoassay (EIA) and polymerase chain reaction (PCR) testing, and to better detect viruses with lymphotropism in biological materials having a concentration of virus particles lower than the sensitivity threshold of existing EIA and PCR methods, thereby making the techniques of the present invention more reliable.

Abstract: The microfluidic platform device of the claimed invention makes use of a high throughput lab-on-a-chip format to determine the functional profile of antibodies elicited by infection or vaccination against infection for any pathogen. It can be used to evaluate vaccines, evaluate whether vaccinated individuals show indices of protection, determine whether individuals display resistance or susceptibility to infection, discover new vaccine antigens, discover and test therapeutic interventions, or evaluate mechanisms of disease.

Abstract: Provided herein are alpha hemolysin polypeptides comprising modified amino acid sequences that can reduce the rate of translocation of a polymer. Also provided herein are apparatuses and devices comprising modified hemolysin polypeptides. Also provided herein are methods of using modified alpha hemolysin proteins for use in characterizing and/or sequencing a polymer or for use as molecular sensors.

Abstract: A method and system to monitor and autonomously configure an intravascular assembly without medical staff involvement or presence. In this solution, a robotic device is associated with an intravascular assembly, which has tubing through which fluids are delivered intravenously. Monitoring of the tubing is initiated. In response to the monitoring, an errant flow through the tubing is detected; typically, the errant flow results from one of: a kink or twist in the tubing, an air bubble in the tubing, an occlusion or clot in the tubing, and pressure variations. In response to detecting the errant flow, and in advance of an audible alarm being generated in association with the intravascular assembly, a command is then issued to the associated robotic device. The command is configured to initiate, by the robotic device, physical engagement with and mechanical manipulation of the tubing, thereby remediating the errant flow automatically.

Abstract: The technology as disclosed herein relates to methods, compositions and kits for multiplex measuring levels of expression of target RNA species (e.g., mRNA and non-coding RNAs) in single, living cells. Aspects of the invention relate to, in part, a duplex-binding protein which is labeled with a FRET dye, and a RNA-binding probe, which comprises a spectrally paired FRET dye and specifically hybridizes to a target RNA. When the RNA-binding probe binds to a target RNA, a duplex is formed, which is allows binding of the duplex-binding protein bringing the two FRET dyes into close proximity and allowing fluorescence resonance energy transfer (FRET) reaction and a detectable change in fluorescence, which determines the amount of target RNA species in the living cell. Aspects of the invention also include, kits, vectors and polynucleic acid sequences of the duplex-binding protein and RNA-binding probes disclosed herein, and cell and cell lines comprising the same.

Abstract: The present invention provides methods and systems for the capture and enrichment of target nucleic acids and analysis of the enriched target nucleic acids. In particular, the present invention provides for the enrichment of targeted sequences in a solution based format.

Abstract: The present invention is related to a parallel line biochip for multiplex diagnosis. The parallel line biochip for multiplex diagnosis includes a plurality of line strips disposed in parallel, and a well configured to immobilize the line strips. Since the parallel line biochip for multiplex diagnosis can be used to connect two or more line strips in parallel, the parallel line biochip for multiplex diagnosis has an effect of measuring various materials present in a biological test sample at the same time.

Abstract: Disclosed herein are methods for the generation of highly accurate nucleic acid libraries encoding for predetermined variants of a nucleic acid sequence. The nucleic acid sequence may encode for all or part of a reference domain of a CAR. The degree of variation may be complete, resulting in a saturated variant library, or less than complete, resulting in a non-saturating library of variants. The variant nucleic acid libraries described herein may be designed for further processing by transcription or translation. The variant nucleic acid libraries described herein may be designed to generate variant RNA, DNA and/or protein populations. Further provided herein are method for identifying variant species with increased or decreased activities, with applications in regulating biological functions and the design of therapeutics for treatment or reduction of a disease, such as cancer.

Abstract: Methods for preventing aggregation of detection particles in a test for detecting a multi-epitope target analyte comprising two or more similar or identical epitopes in a sample and/or for determining the concentration of the multi-epitope target analyte in a sample by applying a first capture entity which can specifically bind to at least one epitope on the multi-epitope analyte and block the at least one epitope from binding to a detection particle. The detection of the multi-epitope target analyte may further include the use of a second capture entity, which can specifically bind to the same or a similar epitope of the multi-epitope target analyte as the first capture entity. The multi-epitope target may be detected through the use of a system comprising a sensor surface and the use of a first capture entity to block the at least one epitope from binding to a detection particle.

Abstract: Methods for the rapid detection of the presence or absence of Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) in a biological or non-biological sample are described. The methods can include performing an amplifying step, a hybridizing step, and a detecting step. Furthermore, primers, probes targeting the genes for HSV-1 viral DNA polymerase B (HSV-1 Pol) and HSV-1 thymidine kinase C (HSV-1 TK), and also target the genes for HSV-2 thymidine kinase C (HSV-2 TK) and HSV-2 glycoprotein B (HSV-2 gB), along with kits are provided that are designed for the detection of HSV-1 and/or HSV-2.

Abstract: The present disclosure relates to improved methods for the isolation of genomic material and detection of disease related single nucleotide polymorphisms. In some aspects, these methods increase the total recovery of genomic DNA from buccal cell samples by improving cell lysis conditions. In other aspects, these methods allow for the reuse of patient buccal swab samples, reducing the likelihood of having to collect additional patient samples for re-testing. Finally, in some aspects, these methods increase the sensitivity of SNP detection using an improved real-time PCR assay protocol.

Abstract: The present invention provides a method of inhibiting hepatitis E virus (HEV) release from a cell that is infected with an HEV, and a method of treating a HEV infection in a subject in need thereof. The present invention also provides a method of identifying agent that inhibits HEV infectivity using a transcomplementation system.

Abstract: A device and method for detecting the presence of a target analyte in a fluid sample are provided. The device can include an inclined capillary tube for transporting a sample fluid containing a sample and functionalized magnetic beads. The functionalized magnetic beads capture the target analyte from the sample fluid. A well is coupled with the inclined capillary tube for containing a developer solution and for receiving the sample fluid. In at least one embodiment a magnet is movably attached to the inclined capillary tube for attracting the magnetic beads of the sample fluid and moving the magnetic beads into the well. A calorimeter is disposed adjacent to the well for receiving heat output from a reaction caused by an enzyme reaction associated with the captured target analyte in the developer solution thereby allowing detection and quantification of the target analyte.

Abstract: Reduced graphene oxide is produced by adding graphene oxide and electrically active bacteria to a container. After a period of time reduced graphene oxide is produced by an interaction of the electrically active bacteria and the graphene oxide. The resulting composition of matter includes reduced graphene oxide and electrically active bacteria. The resulting composition of matter can be doped with a plurality of different elements.

Abstract: There is provided a non-PCR based method for construction of a DNA recombination fragment with necessary flanking regions homologous to a desired site of genetic manipulation within a target DNA required for recombination-based manipulation of said target DNA, comprising the steps of: A) identifying a desired site of insertion for a genetic element in said target DNA; B) locating an endogenous, native, half-site of a selected restriction endonuclease present upstream of the site within the DNA to be targeted for genetic manipulation and thereby defining the 5? extent of an upstream homology region; C) locating an endogenous, native, half-site of the same selected restriction endonuclease present downstream of the site within the DNA to be targeted for genetic manipulation and thereby defining the 3? extent of a downstream homology region; D) synthesising a flanking region cassette resulting in juxtapositioning of the upstream and downstream half-sites thereby causing formation of complete restriction site for

Abstract: A test element for an assay includes: a cartridge having a housing which includes a priming pad capable of containing a liquid fluid, a wash port having an opening in the housing, and an opening for directly or indirectly applying a sample; and an assay device positioned within the cartridge in fluid communication with the wash port containing an analytical reagent.

Abstract: Ultra-sensitive assays for the detection of mutations, e.g., from blood-based sources of tumor genetic material (circulating tumor cells or plasma), or other settings in which limiting amounts of DNA, e.g., tumor DNA, is available. The assay is exemplified in the estrogen receptor, but is broadly customizable to target mutations in other genes.

Abstract: Hepatitis E virus (HEV) is responsible for over 50% of acute viral hepatitis cases worldwide. The inventors have now identified the precise sequence of infectious particle-associated ORF2 capsid protein. Strikingly, their analyses revealed that in infected patients, HEV produces three forms of the ORF2 capsid protein: ORF2i, ORF2g and ORF2c. The ORF2i protein is associated with infectious particles whereas ORF2g and ORF2c proteins are massively produced glycoproteins that are not associated with infectious particles and are the major antigens present in HEV-infected patient sera. Accordingly, the ORF2i and ORF2g proteins are thus the subject matter of the present invention as well as antibodies specific for the proteins and diagnostic assays (e.g. ELISA) for the diagnosis of Hepatitis E virus infection.

Abstract: A method is provided herein, wherein the method of capturing a target nucleic acid, comprises applying a nucleic acid capture probe to a capture zone of a needs definition, wherein the nucleic acid capture probe having a first molecular weight comprises at least a sequence that is complimentary to at least a portion of the target nucleic acid sequence and the nucleic acid capture probe is substantially immobilized at the capture zone of the substrate. The method further comprises applying a sample comprising the target nucleic acid having a second molecular weight to a sample application zone of the substrate; wherein the sample comprising the target nucleic acid flows across a length of the substrate from the sample application zone to the capture zone by lateral flow, and the target nucleic acid is captured by the nucleic acid capture probes by hybridization to the capture zone.

Abstract: A real time Taq-Man PCR assay for detecting multiple serotypes of human papillomavirus (HPV) wherein the number of serotypes detected exceeds the number of colorimetric channels for detection. A biological sample is combined with three oligonucleotide primer/probe sets such that the probes and primers anneal to a target sequence. Each primer/probe set is at least preferential for a specific serotype of an organism. The first and second primer/probe sets are degenerate with respect to each other. The third primer/probe set is not degenerate with respect to the first and second primer/probe sets and discriminates for a third serotype. The third primer/probe set has a signal moiety that emits signal at a wavelength that is the same or different from the wavelength emitted by the signal moiety of the degenerate primer/probe set probes. The target sequences, if present, are amplified and detected.